Long-term effectiveness of a new α-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated Type 2 diabetes mellitus

• Published in: Diabetic medicine 1998-08, Vol.15 (8), p.657-660
• Main Authors: Mitrakou, A., Tountas, N., Raptis, A.E., Bauer, R.J., Schulz, H., Raptis, S.A.
• Format: Article
• Language: English
• Subjects: 1-Deoxynojirimycin - analogs & derivatives; Adult; Aged; Biological and medical sciences; Blood Glucose - metabolism; C-Peptide - blood; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - therapeutic use; Fasting; Female; Follow-Up Studies; General and cellular metabolism. Vitamins; Glucosamine - adverse effects; Glucosamine - analogs & derivatives; Glucosamine - therapeutic use; Glycated Hemoglobin A - analysis; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Imino Pyranoses; Insulin - therapeutic use; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Postprandial Period; Time Factors
• ISSN: 0742-3071; 1096-9136; 1464-5491
• DOI: 10.1002/(SICI)1096-9136(199808)15:8<657::AID-DIA652>3.0.CO;2-7

In a double‐blind, randomized study, miglitol (BAY m 1099), an α‐glucosidase inhibitor, 100 mg tds or placebo was given orally with meals for a period of 24 weeks in 117 patients with Type 2 (non‐insulin‐dependent) diabetes mellitus (DM) treated with insulin. Fasting and 1 h postprandial plasma glucose and C‐peptide were measured at the beginning and at the end of each 4‐week interval and glycosylated haemoglobin was determined at day 0 and at the end of the 12th and 24th week. One hour postprandial plasma glucose was significantly lower in the miglitol group at the end of the 24th week (placebo: 11.6 ± 1.5 vs miglitol: 8.2 ± 1.5 mmol l−1, mean ± SD, p = 0.001). Diabetes control improved in the same group as the HbA1 was lowered by 16 % (p =